Beam Therapeutics (BEAM) Cash from Financing Activities (2019 - 2026)

Beam Therapeutics (BEAM) has reported Cash from Financing Activities for 8 consecutive years, with $96.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 79.59% year-over-year to $96.6 million; the TTM figure through Mar 2026 stood at $101.3 million (down 78.82% YoY), while the FY2025 annual figure was $478.0 million, up 6079.54% from the prior year.
• Cash from Financing Activities climbed to $96.6 million in Q1 2026 per BEAM's latest filing, from $1.9 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $473.4 million in Q1 2025 and bottomed at $133000.0 in Q2 2024.
• Historically, Cash from Financing Activities has averaged $57.1 million across 5 years, with a median of $22.3 million in 2022.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities slumped 99.88% — and 2025, when it jumped 16240.32%.
• Beam Therapeutics' Cash from Financing Activities stood at $32.0 million in 2022, then gained by 5.31% to $33.7 million in 2023, then plunged by 89.78% to $3.4 million in 2024, then sank by 45.24% to $1.9 million in 2025, then surged by 5022.38% to $96.6 million in 2026.
• Business Quant data shows BEAM's Cash from Financing Activities at $96.6 million in Q1 2026, $1.9 million in Q4 2025, and $1.7 million in Q3 2025.